Teva Pharmaceutical Industries (TEVA) Given a $22.00 Price Target by Royal Bank of Canada Analysts

Teva Pharmaceutical Industries (NYSE:TEVA) received a $22.00 price target from investment analysts at Royal Bank of Canada in a research report issued to clients and investors on Friday. The firm currently has a “hold” rating on the stock. Royal Bank of Canada’s price objective points to a potential downside of 2.61% from the company’s current price.

Several other analysts have also commented on TEVA. Mizuho reiterated a “buy” rating and set a $28.00 price objective on shares of Teva Pharmaceutical Industries in a report on Thursday, August 16th. Wells Fargo & Co set a $23.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, August 2nd. Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a report on Monday, July 9th. Finally, Credit Suisse Group lowered Teva Pharmaceutical Industries from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $25.00 to $23.00 in a report on Friday, September 7th. Five investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $21.26.

Teva Pharmaceutical Industries stock traded down $0.41 during mid-day trading on Friday, reaching $22.59. 11,391,865 shares of the company were exchanged, compared to its average volume of 10,241,511. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 1.86. The firm has a market cap of $22.97 billion, a P/E ratio of 7.04, a P/E/G ratio of 1.86 and a beta of 0.77. Teva Pharmaceutical Industries has a 12-month low of $10.91 and a 12-month high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.53 by $0.11. The company had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.54 billion. Teva Pharmaceutical Industries had a positive return on equity of 21.69% and a negative net margin of 54.67%. Teva Pharmaceutical Industries’s revenue was down 19.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.00 earnings per share. Equities analysts expect that Teva Pharmaceutical Industries will post 2.72 earnings per share for the current year.

In related news, insider Deborah A. Griffin sold 2,376 shares of the company’s stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total value of $56,334.96. Following the transaction, the insider now directly owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Iris Beck Codner sold 4,165 shares of the company’s stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $22.70, for a total value of $94,545.50. Following the completion of the transaction, the executive vice president now directly owns 8,290 shares in the company, valued at $188,183. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,350 shares of company stock worth $239,430. 0.43% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Dimensional Fund Advisors LP increased its position in shares of Teva Pharmaceutical Industries by 16.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,185,541 shares of the company’s stock valued at $20,261,000 after acquiring an additional 168,658 shares during the period. Legal & General Group Plc grew its position in Teva Pharmaceutical Industries by 14.6% during the 1st quarter. Legal & General Group Plc now owns 611,919 shares of the company’s stock worth $10,458,000 after purchasing an additional 77,766 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter worth about $293,000. DnB Asset Management AS grew its position in Teva Pharmaceutical Industries by 13.6% during the 2nd quarter. DnB Asset Management AS now owns 77,700 shares of the company’s stock worth $1,890,000 after purchasing an additional 9,300 shares during the period. Finally, IFM Investors Pty Ltd grew its position in Teva Pharmaceutical Industries by 52.8% during the 2nd quarter. IFM Investors Pty Ltd now owns 43,300 shares of the company’s stock worth $1,053,000 after purchasing an additional 14,960 shares during the period. 64.73% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Return on Investment (ROI) Defined, Explained

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply